Literature DB >> 16924242

Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells.

I V Lebedeva1, Z-Z Su, L Emdad, A Kolomeyer, D Sarkar, S Kitada, S Waxman, J C Reed, P B Fisher.   

Abstract

Melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) is a cancer-specific, growth-suppressing and apoptosis-inducing gene with broad-spectrum antitumor activity. However, when administered by means of a replication-incompetent adenovirus, Ad.mda-7, several colorectal carcinoma cell lines are resistant to its antiproliferative and antisurvival effects. We have presently endeavored to determine if K-ras mutations, present in approximately 40-50% of colorectal cancers and which may mediate resistance to chemotherapy and radiotherapy, represent a predisposing genetic factor mitigating reduced sensitivity to Ad.mda-7. To suppress ras expression, three structurally different replication-incompetent adenoviral vectors were engineered that express (1) an intracellular, neutralizing single-chain antibody (scAb) to p21 ras (Ad.K-ras scAb), (2) an antisense (AS) K-ras gene (Ad.K-ras AS) or (3) both mda-7/IL-24 and a K-ras AS gene in a single bipartite virus (Ad.m7.KAS). Simultaneous inhibition of K-ras and expression of mda-7/IL-24 enhanced killing of colorectal carcinoma cells with mutated K-ras, but not with wild-type K-ras. The extent of killing depended on the degree of K-ras downregulation, with Ad.K-ras AS being generally more efficient than Ad.K-ras scAb in combination with Ad.mda-7. These findings support an effective dual-combinatorial approach for the therapy of colorectal cancers that employs a unique cancer-specific suppressor gene (mda-7/IL-24) with targeted inhibition of oncogene (ras) expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16924242     DOI: 10.1038/sj.onc.1209813

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Characterization of the canine mda-7 gene, transcripts and expression patterns.

Authors:  Maninder Sandey; R Curtis Bird; Swadesh K Das; Devanand Sarkar; David T Curiel; Paul B Fisher; Bruce F Smith
Journal:  Gene       Date:  2014-05-24       Impact factor: 3.688

2.  mda-7/IL-24 Mediates Cancer Cell-Specific Death via Regulation of miR-221 and the Beclin-1 Axis.

Authors:  Anjan K Pradhan; Sarmistha Talukdar; Praveen Bhoopathi; Xue-Ning Shen; Luni Emdad; Swadesh K Das; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Res       Date:  2016-12-09       Impact factor: 12.701

3.  Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis.

Authors:  Moira Sauane; Zao-Zhong Su; Pankaj Gupta; Irina V Lebedeva; Paul Dent; Devanand Sarkar; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-03       Impact factor: 11.205

4.  Enhanced therapeutic effects for human pancreatic cancer by application K-ras and IGF-IR antisense oligodeoxynucleotides.

Authors:  Yong-Mei Shen; Xiao-Chun Yang; Chen Yang; Jun-Kang Shen
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

5.  Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate Indolo[3,2-b]quinoline Tri-Alkylamine Derivatives.

Authors:  Hugo Brito; Ana Cláudia Martins; João Lavrado; Eduarda Mendes; Ana Paula Francisco; Sofia A Santos; Stephan A Ohnmacht; Nam-Soon Kim; Cecília M P Rodrigues; Rui Moreira; Stephen Neidle; Pedro M Borralho; Alexandra Paulo
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

Review 6.  Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic.

Authors:  Luni Emdad; Praveen Bhoopathi; Sarmistha Talukdar; Anjan K Pradhan; Devanand Sarkar; Xiang-Yang Wang; Swadesh K Das; Paul B Fisher
Journal:  Semin Cancer Biol       Date:  2019-07-26       Impact factor: 15.707

7.  Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV).

Authors:  Belal M Azab; Rupesh Dash; Swadesh K Das; Sujit K Bhutia; Siddik Sarkar; Xue-Ning Shen; Bridget A Quinn; Paul Dent; Igor P Dmitriev; Xiang-Yang Wang; David T Curiel; Maurizio Pellecchia; John C Reed; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2014-01       Impact factor: 6.384

8.  Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.

Authors:  Ana de la Cueva; Ana Ramírez de Molina; Néstor Alvarez-Ayerza; Ma Angeles Ramos; Arancha Cebrián; Teresa Gómez Del Pulgar; Juan Carlos Lacal
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

9.  MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice.

Authors:  Susanna Cogoi; Sonia Zorzet; Valentina Rapozzi; Imrich Géci; Erik B Pedersen; Luigi E Xodo
Journal:  Nucleic Acids Res       Date:  2013-03-06       Impact factor: 16.971

10.  BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt.

Authors:  I Pal; S Sarkar; S Rajput; K K Dey; S Chakraborty; R Dash; S K Das; D Sarkar; E Barile; S K De; M Pellecchia; P B Fisher; M Mandal
Journal:  Br J Cancer       Date:  2014-06-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.